Zacks: Analysts expect Baxter International Inc. (NYSE: BAX) to report earnings of $0.88 per share


Brokerages expect Baxter International Inc. (NYSE: BAXGet a rating) will report earnings of $0.88 per share for the current quarter, according to Zacks. Seven analysts provided earnings estimates for Baxter International, with the lowest EPS estimate of $0.87 and the highest estimate of $0.89. Baxter International reported earnings per share of $0.80 in the same quarter last year, suggesting a positive 10% year-over-year growth rate. The company is due to announce its next results on Monday, January 1.

According to Zacks, analysts expect Baxter International to report annual earnings of $4.16 per share for the current fiscal year, with EPS estimates ranging from $4.12 to $4.18. For next year, analysts expect the company to post earnings of $4.73 per share, with EPS estimates ranging from $4.53 to $4.85. Zacks earnings per share calculations are an average average based on a survey of analysts who follow Baxter International.

Baxter International (NYSE: BAXGet a rating) last released its quarterly earnings data on Thursday, April 28. The medical device supplier reported earnings per share of $0.93 for the quarter, beating the consensus estimate of $0.80 by $0.13. Baxter International had a return on equity of 21.59% and a net margin of 7.80%. The company posted revenue of $3.71 billion in the quarter, versus $3.68 billion expected by analysts. In the same quarter last year, the company posted EPS of $0.76. The company’s revenue increased 25.8% year over year.

BAX has been the subject of a number of research analyst reports. Goldman Sachs Group downgraded Baxter International from a “neutral” rating to a “sell” rating and lowered its target price for the company from $88.00 to $77.00 in a Monday, April 4 research note. . Wells Fargo & Company lowered its price target on Baxter International from $95.00 to $93.00 and set an “overweight” rating for the company in a Friday, Feb. 18 research note. TheStreet upgraded Baxter International from a “b-” rating to a “c” rating in a Thursday, April 28 research note. StockNews.com launched coverage on Baxter International in a research note on Thursday, March 31. They issued a “holding” rating for the company. To finish, Zacks Investment Research upgraded Baxter International from a “sell” rating to a “hold” rating and set a target price of $77.00 for the company in a Tuesday, May 10 research note. One research analyst rated the stock with a sell rating, four gave the stock a hold rating, and eleven gave the stock a buy rating. According to data from MarketBeat.com, Baxter International currently has a consensus buy rating and a consensus target price of $89.92.

NYSE Stock Exchange opened at $72.54 on Friday. The stock has a market capitalization of $36.53 billion, a P/E ratio of 34.71, a price-to-earnings growth ratio of 1.63 and a beta of 0.62. The company has a debt ratio of 1.84, a quick ratio of 1.45 and a current ratio of 2.10. The stock has a 50-day simple moving average of $75.01 and a two-hundred-day simple moving average of $80.25. Baxter International has a fifty-two week minimum of $69.71 and a fifty-two week maximum of $89.70.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 1. Shareholders of record on Friday, June 3 will receive a dividend of $0.29. This is an increase from Baxter International’s previous quarterly dividend of $0.28. This represents a dividend of $1.16 on an annualized basis and a dividend yield of 1.60%. The ex-date of this dividend is Thursday, June 2. Baxter International’s dividend payout ratio (DPR) is 55.50%.

In other news, Director Albert PL Stroucken sold 4,020 shares of the company in a trade on Tuesday, April 5. The stock was sold at an average price of $76.02, for a total value of $305,600.40. As a result of the transaction, the administrator now directly owns 27,629 shares of the company, valued at approximately $2,100,356.58. The transaction was disclosed in a document filed with the SEC, accessible via this link. Insiders of the company own 0.21% of the shares of the company.

Several hedge funds have recently increased or reduced their holdings in BAX. Geode Capital Management LLC increased its position in Baxter International by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 8,719,597 shares of the medical device supplier valued at $746,523,000 after purchasing an additional 540,182 shares last quarter. UBS Asset Management Americas Inc. increased its position in Baxter International by 0.9% during the third quarter. UBS Asset Management Americas Inc. now owns 2,551,540 shares of the medical device supplier valued at $205,220,000 after purchasing an additional 22,839 shares last quarter. Parametric Portfolio Associates LLC increased its position in Baxter International by 5.9% during the fourth quarter. Parametric Portfolio Associates LLC now owns 2,024,918 shares of the medical device supplier valued at $173,819,000 after purchasing an additional 113,578 shares last quarter. Neuberger Berman Group LLC increased its position in Baxter International by 2,202.6% during the first quarter. Neuberger Berman Group LLC now owns 1,650,719 shares of the medical device supplier valued at $128,029,000 after purchasing an additional 1,579,029 shares last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in Baxter International by 3.0% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,496,291 shares of the medical device supplier valued at $116,022,000 after buying an additional 44,164 shares last quarter. Hedge funds and other institutional investors own 86.65% of the company’s shares.

About Baxter International (Get a rating)

Baxter International Inc, through its subsidiaries, develops and supplies a portfolio of healthcare products worldwide. The Company offers peritoneal dialysis and hemodialysis, as well as additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets and drug reconstitution devices; remix and oncology drug platforms, inhaled anesthesia and intensive care products and pharmaceutical preparation services; parenteral nutritional therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and prevention of adhesions; and ongoing renal replacement therapies and other organ support therapies focused in the intensive care unit.

Recommended Stories

Get a Free Copy of Zacks’ Research Report on Baxter International (BAX)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Baxter International (NYSE: BAX) Earnings History and Estimates



Get news and reviews for Baxter International Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Baxter International and related companies with MarketBeat.com’s FREE daily email newsletter.

Comments are closed.